Endogenex
Minneapolis, US · Founded 2017 · 28 employees on LinkedIn · 4 known investors
Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
Founders & leadership
SP
Stacey PughLeadership (CEO)
CS
Chris Sorli, MD, PhDinChief Medical Officer
KW
Krissy WrightinChief Financial Officer
LC
Lian Cunningham, MD, PhDinVP Clinical Affairs
MH
Melanie HessinRegulatory Affairs Leadership
MC
Matt CambronneinTechnical/Engineering Leadership
BK
Barham K. Abu DayyehCo-inventor, pulsENDO system
Investors · 4
Funding
SEC filings, press & company announcements- Undisclosed amountSeries C ExtensionMar 2026 · 2 sourcesSource ↗
- Undisclosed amountSeries CJun 2024Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 4
by search overlapBioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Orogentx8 shared keywordsOrogen Therapeutics is a drug discovery company that uses AI-enabled DNA-encoded library (DEL) technology and machine learning to identify novel small-molecule compounds targeting cytokine-related immuno-inflammatory disorders. The company focuses on developing oral small-molecule candidates for therapeutic areas including dermatology, rheumatology, and gastroenterology.
Phigenix7 shared keywordsPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.
argenx7 shared keywordsargenx is an immunology company that operates an antibody innovation ecosystem where scientists and antibody engineers develop novel targets, disease pathways, and therapeutic antibodies. It builds a proprietary portfolio of first-in-class product candidates, engineered with academic partners, to translate immunology research into medicines for patients.
Companies competing with Endogenex for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Endogenex do?
- Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
- Who are Endogenex's investors?
- Endogenex's investors include Arboretum Ventures, Intuitive Ventures, Longitude Capital, Lumira Ventures.
- Where is Endogenex headquartered?
- Endogenex is headquartered in Minneapolis, US.